OPKO Health Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPKO Health stock.
View analyst ratings for OPKO Health or view top-rated stocks.

Wall Street analysts have given OPKO Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OPKO Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

OPKO Health is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for OPKO Health.

OPKO Health, Inc. (NASDAQ:OPK) posted its quarterly earnings results on Thursday, July, 29th. The biotechnology company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.02 by $0.05. OPKO Health had a trailing twelve-month return on equity of 4.21% and a net margin of 3.71%.
View OPKO Health's earnings history.

OPKO Health's stock was trading at $1.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OPK shares have increased by 113.6% and is now trading at $3.61.
View which stocks have been most impacted by COVID-19.

2 analysts have issued 1-year price targets for OPKO Health's stock. Their forecasts range from $6.00 to $7.00. On average, they expect OPKO Health's share price to reach $6.50 in the next year. This suggests a possible upside of 80.1% from the stock's current price.
View analysts' price targets for OPKO Health or view top-rated stocks among Wall Street analysts.

21 employees have rated OPKO Health CEO Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among OPKO Health's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to OPKO Health include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of OPK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

OPKO Health trades on the NASDAQ under the ticker symbol "OPK."

OPKO Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Landscape Capital Management L.L.C. (0.13%), Victory Capital Management Inc. (0.10%), Alliancebernstein L.P. (0.09%), New York State Common Retirement Fund (0.05%), Advisor Group Holdings Inc. (0.03%) and Aperimus Capital LLC (0.03%). Company insiders that own OPKO Health stock include Anthony J Japour, Jane Ph D Hsiao, Jon R Cohen, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert J Shovlin and Steven D Rubin.
View institutional ownership trends for OPKO Health.

OPK stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., New York State Common Retirement Fund, and Arizona State Retirement System.
View insider buying and selling activity for OPKO Health or view top insider-selling stocks.

OPK stock was bought by a variety of institutional investors in the last quarter, including Landscape Capital Management L.L.C., Victory Capital Management Inc., Aperimus Capital LLC, Fairfield Bush & CO., Kestra Private Wealth Services LLC, Handelsbanken Fonder AB, KLCM Advisors Inc., and Teamwork Financial Advisors LLC. Company insiders that have bought OPKO Health stock in the last two years include Anthony J Japour, Jane Ph D Hsiao, Jon R Cohen, Phillip Md Et Al Frost, Richard C Pfenniger Jr, and Steven D Rubin.
View insider buying and selling activity for OPKO Health or or view top insider-buying stocks.

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPK stock can currently be purchased for approximately $3.61.

OPKO Health has a market capitalization of $2.42 billion and generates $1.44 billion in revenue each year. The biotechnology company earns $30.59 million in net income (profit) each year or $0.05 on an earnings per share basis.

OPKO Health employs 5,269 workers across the globe.

The official website for OPKO Health is www.opko.com.

OPKO Health is headquartered at 4400 BISCAYNE BLVD., MIAMI FL, 33137.

OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at (305) 575-4100 or via email at [email protected]